BRPI0914231A2 - composto, composição farmacêutica, método para tratar um distúrbio psiquiátrico, e, uso de um composto - Google Patents

composto, composição farmacêutica, método para tratar um distúrbio psiquiátrico, e, uso de um composto

Info

Publication number
BRPI0914231A2
BRPI0914231A2 BRPI0914231A BRPI0914231A BRPI0914231A2 BR PI0914231 A2 BRPI0914231 A2 BR PI0914231A2 BR PI0914231 A BRPI0914231 A BR PI0914231A BR PI0914231 A BRPI0914231 A BR PI0914231A BR PI0914231 A2 BRPI0914231 A2 BR PI0914231A2
Authority
BR
Brazil
Prior art keywords
compound
treating
pharmaceutical composition
psychiatric disorder
psychiatric
Prior art date
Application number
BRPI0914231A
Other languages
English (en)
Portuguese (pt)
Inventor
Ashokkumar Bhikkappa Shenvi
Dan Widzowski
Dean Brown
James Campbell Muir
James Hulsizer
James R Damewood
M Edward Pierson Jr
Michael Wood
Phil Edwards
Steven Wesolowski
Original Assignee
Atrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41431860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914231(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atrazeneca Ab filed Critical Atrazeneca Ab
Publication of BRPI0914231A2 publication Critical patent/BRPI0914231A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0914231A 2008-06-20 2009-06-18 composto, composição farmacêutica, método para tratar um distúrbio psiquiátrico, e, uso de um composto BRPI0914231A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7441708P 2008-06-20 2008-06-20
PCT/SE2009/050763 WO2009154563A1 (en) 2008-06-20 2009-06-18 Dibenzothiazepine derivatives and use thereof

Publications (1)

Publication Number Publication Date
BRPI0914231A2 true BRPI0914231A2 (pt) 2015-11-03

Family

ID=41431860

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914231A BRPI0914231A2 (pt) 2008-06-20 2009-06-18 composto, composição farmacêutica, método para tratar um distúrbio psiquiátrico, e, uso de um composto

Country Status (37)

Country Link
US (3) US20110160184A1 (https=)
EP (1) EP2307389B1 (https=)
JP (2) JP5468068B2 (https=)
KR (1) KR20110019781A (https=)
CN (1) CN102131791B (https=)
AR (1) AR072200A1 (https=)
AU (1) AU2009260905B2 (https=)
BR (1) BRPI0914231A2 (https=)
CA (1) CA2728675A1 (https=)
CL (1) CL2010001471A1 (https=)
CR (1) CR11860A (https=)
CU (1) CU23884B1 (https=)
CY (1) CY1113845T1 (https=)
DK (1) DK2307389T3 (https=)
DO (1) DOP2010000393A (https=)
EA (1) EA201001889A1 (https=)
EC (1) ECSP10010698A (https=)
ES (1) ES2402084T3 (https=)
HN (1) HN2010002683A (https=)
HR (1) HRP20130234T1 (https=)
IL (2) IL210081A (https=)
ME (1) ME01516B (https=)
MX (1) MX2010014203A (https=)
MY (1) MY157518A (https=)
NI (1) NI201000224A (https=)
NZ (1) NZ590616A (https=)
PE (1) PE20110029A1 (https=)
PL (1) PL2307389T3 (https=)
PT (1) PT2307389E (https=)
RS (1) RS52703B (https=)
SI (1) SI2307389T1 (https=)
SV (1) SV2010003769A (https=)
TW (1) TWI488854B (https=)
UA (1) UA105903C2 (https=)
UY (1) UY31919A (https=)
WO (1) WO2009154563A1 (https=)
ZA (1) ZA201100488B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010014203A (es) * 2008-06-20 2011-02-22 Astrazeneca Ab Derivados de dibenzotiazepina y sus usos - 424.
CN105981027A (zh) * 2013-08-12 2016-09-28 哥莱菲特软件公司 安全认证并切换至加密域
CN103524455A (zh) * 2013-10-30 2014-01-22 苏州敬业医药化工有限公司 一种制备2-氯-二苯并[b,f][1,4]硫氮杂卓-11-[10H]酮的方法
CN106134230A (zh) 2013-11-21 2016-11-16 哥莱菲特软件公司 用于移动信息设备上的远程内容和配置控制的管理域
CN104447615A (zh) * 2014-02-28 2015-03-25 广东东阳光药业有限公司 喹硫平中间体的制备方法
EP4676594A1 (en) * 2023-03-08 2026-01-14 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Slack-activating compounds and their medical use
EP4428132A1 (en) * 2023-03-08 2024-09-11 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Slack-activating compounds and their medical use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL294355A (https=)
NL293201A (https=)
DE1620703B2 (de) * 1960-08-16 1976-11-25 Ausscheidung aus: 12 80 879 Dr. A. Wander AG, Bern 11-basisch substituierte dibenzo eckige klammer auf b,f eckige klammer zu-eckige klammer auf 1,4 eckige klammer zu-thiazepine
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
DE1620711A1 (de) 1962-05-25 1970-06-04 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter 5H-Dibenzo[b,e][1,4]diazepine
CH476743A (de) 1962-06-08 1969-08-15 Wander Ag Dr A Verfahren zur Herstellung von Amidinen der Dibenzo (b,e) (1,4)-diazepin-Reihe
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
BE632120A (https=) 1963-05-09
US3908010A (en) 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3683034A (en) 1963-09-27 1972-08-08 Upjohn Co Process for the preparation of substituted hydroquinones
US3884920A (en) 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3412193A (en) 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
AT278805B (de) 1966-01-17 1970-02-10 American Cyanamid Co Verfahren zur herstellung von oxazepinen und thiazepinen
NL6715650A (https=) 1966-12-16 1968-06-17
US3852446A (en) 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3758479A (en) 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
CH569730A5 (https=) * 1972-04-04 1975-11-28 Wander Ag Dr A
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
JPH0565257A (ja) 1991-07-05 1993-03-19 Hokuriku Seiyaku Co Ltd 多環式化合物及びその用途
US5750566A (en) 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
JP3708962B2 (ja) 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
WO2001008680A1 (de) 1999-07-28 2001-02-08 Oswald Wiss Präparate mit sauerstoffsparender wirkung bei körperlicher leistung
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AU2002249885A1 (en) 2000-11-17 2002-08-12 Adolor Corporation Delta agonist analgesics
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
DK1395567T3 (da) 2001-05-18 2009-04-06 Astrazeneca Ab 4-(phenylpiperazinylmethyl)-benzamidderivater og deres anvendelse til behandling af smerte, angst eller mavetarmslidelser
DE60218032T2 (de) 2001-06-01 2007-08-16 Astrazeneca Ab Neuer, für die therapie geeigneter ligand für nikotinische acetylcholinrezeptoren
EP1414466B1 (en) 2001-07-09 2009-08-19 CombinatoRx, Incorporated Combinations for the treatment of inflammatory disorders
JP4521187B2 (ja) 2001-09-27 2010-08-11 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド コンジュゲートされた抗精神病薬およびこれらの使用
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7417050B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Heterocyclic compounds
BR0309342A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
EP1499618B1 (en) 2002-04-18 2010-10-13 AstraZeneca AB Furyl compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
CN1681388A (zh) 2002-09-18 2005-10-12 Fmc有限公司 三环衍生物杀虫剂
AU2003290079A1 (en) 2002-12-20 2004-07-14 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
CN1741803A (zh) 2003-01-23 2006-03-01 阿卡蒂亚药品公司 N－脱甲基氯氮平在治疗人神经精神疾病中的用途
EP1495008A1 (en) 2003-02-22 2005-01-12 Teva Pharmaceutical Industries Limited Synthesis of quetiapine and pharmaceutically acceptable salts thereof
DE10310196A1 (de) 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
JP2006523707A (ja) 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
PL195728B1 (pl) 2003-07-18 2007-10-31 Helm Ag Sposób wytwarzania 11-(1-piperazynylo)dibenzo[b,f][1,4]tiazepiny
SG133606A1 (en) 2003-12-22 2007-07-30 Acadia Pharm Inc Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
RU2394030C2 (ru) * 2003-12-22 2010-07-10 Акадиа Фармасьютикалз Инк. АМИНОЗАМЕЩЕННЫЕ АНАЛОГИ ДИАРИЛ [a,d] ЦИКЛОГЕПТЕНА В КАЧЕСТВЕ МУСКАРИНОВЫХ АГОНИСТОВ И СПОСОБЫ ЛЕЧЕНИЯ ПСИХОНЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
KR20070106690A (ko) 2004-12-27 2007-11-05 아스트라제네카 아베 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도
WO2006073360A1 (en) * 2005-01-07 2006-07-13 Astrazeneca Ab NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
WO2006107948A2 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20100016284A1 (en) 2006-12-20 2010-01-21 Astrazeneca Ab Compounds and uses thereof - 151
CN101605792A (zh) 2007-02-09 2009-12-16 阿斯利康(瑞典)有限公司 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途
US7491871B2 (en) 2007-04-25 2009-02-17 Stine Seed Farm, Inc. Soybean cultivar S060299
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
MX2010014203A (es) * 2008-06-20 2011-02-22 Astrazeneca Ab Derivados de dibenzotiazepina y sus usos - 424.

Also Published As

Publication number Publication date
IL210081A (en) 2013-12-31
AU2009260905B2 (en) 2012-08-23
NZ590616A (en) 2012-09-28
ME01516B (me) 2014-04-20
IL229560A (en) 2015-07-30
US8653257B2 (en) 2014-02-18
HRP20130234T1 (hr) 2013-04-30
PT2307389E (pt) 2013-03-28
NI201000224A (es) 2012-03-19
SV2010003769A (es) 2011-05-20
UY31919A (es) 2010-01-29
DK2307389T3 (da) 2013-04-02
KR20110019781A (ko) 2011-02-28
AR072200A1 (es) 2010-08-11
HK1156308A1 (en) 2012-06-08
US8158618B2 (en) 2012-04-17
US20110160184A1 (en) 2011-06-30
IL210081A0 (en) 2011-02-28
PE20110029A1 (es) 2011-02-11
RS52703B (sr) 2013-08-30
JP2011524898A (ja) 2011-09-08
AU2009260905A1 (en) 2009-12-23
CN102131791B (zh) 2014-12-24
HN2010002683A (es) 2013-01-15
DOP2010000393A (es) 2011-01-31
SI2307389T1 (sl) 2013-04-30
WO2009154563A1 (en) 2009-12-23
CL2010001471A1 (es) 2011-05-06
EP2307389A4 (en) 2012-04-11
ECSP10010698A (es) 2011-01-31
JP2014098006A (ja) 2014-05-29
EA201001889A1 (ru) 2011-08-30
IL229560A0 (en) 2014-01-30
US20090318415A1 (en) 2009-12-24
MX2010014203A (es) 2011-02-22
EP2307389A1 (en) 2011-04-13
TWI488854B (zh) 2015-06-21
EP2307389B1 (en) 2013-01-23
CY1113845T1 (el) 2016-07-27
TW201002702A (en) 2010-01-16
MY157518A (en) 2016-06-15
PL2307389T3 (pl) 2013-05-31
JP5468068B2 (ja) 2014-04-09
CN102131791A (zh) 2011-07-20
ES2402084T3 (es) 2013-04-26
CU23884B1 (es) 2013-04-19
CU20100252A7 (es) 2011-11-15
CA2728675A1 (en) 2009-12-23
CR11860A (es) 2011-02-25
ZA201100488B (en) 2011-10-26
UA105903C2 (uk) 2014-07-10
US20120202991A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BRPI0814777A2 (pt) Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BRPI0909691A8 (pt) composto, método para preparar um composto, e, composição farmacêutica
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0914927A2 (pt) composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
BRPI0610514A2 (pt) composto, composição farmacêutica, e, método de tratamento de um distúrbio
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0908252A2 (pt) Processo para preparar um composto, e, uso de um composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0822946A2 (pt) Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida
BRPI0811238A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método para tratar um distúrbio
BRPI0908883A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1012978A2 (pt) composição tópica, método para preparar a mesma, e, uso de um composto
BR112012004173A2 (pt) "composto, composição, método para preparar uma composição, e, uso de um composto"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]